Caribou has an extensive CRISPR technology IP portfolio, including an exclusive license to the foundational CRISPR-Cas9 work from the University of California and the University of Vienna. Caribou licenses its technology to strategic partners who are recognized leaders in target market sectors. For information regarding licensing, click here. In addition to licensing, Caribou is interested in strategic opportunities that will allow us to expand our research and development and work together with other companies toward future breakthroughs across the full breadth of CRISPR technology’s potential. To find out more about prospective collaborations, click here.
Caribou has entered into licenses with recognized leaders in many market sectors. Such licenses include:
Caribou and Pioneer Hi-Bred International, Inc. (now a member of the Corteva Agriscience™ group of companies, “Corteva”), announced a license agreement and multi-year collaboration in 2015, including the cross-licensing of key intellectual property. Both Corteva and Caribou control patent portfolios covering multiple foundational CRISPR technologies. The cross-license enables Caribou to develop and utilize CRISPR-Cas technology for product development in a variety of fields including therapeutics, industrial biotechnology, research tools, and certain agriculture segments. The Corteva license to Caribou includes rights to the Cas9-mediated genome editing intellectual property owned by Vilnius University and exclusively licensed to Corteva and other CRISPR intellectual property owned by the Nutrition and Biosciences division of DuPont de Nemours, Inc. Caribou is eligible to receive milestone payments for products commercialized by Corteva in certain fields. Corteva is an investor in Caribou’s Series A and Series B financing rounds. View Press Release.
In 2016, Caribou entered a multi-year strategic research collaboration with Genus plc under which Caribou has provided Genus with exclusive access to Caribou’s CRISPR-Cas9 technology for the development of new traits in pigs, cattle, and potentially other livestock species. Among the first targets of the program are the further development and optimization of Genus’ Porcine Reproductive and Respiratory Syndrome Virus (PRRSv) resistant pigs and development of cattle resistant to Bovine Respiratory Disease (BRD). Caribou is eligible to receive regulatory and commercial milestone payments from Genus as well as royalties on licensed product sales. The partnership positions Caribou and Genus at the forefront of an emerging market for which CRISPR-Cas9 could have profound benefits to animal well-being and health. Genus is an investor in Caribou’s Series B financing round. View Press Release.
Helmholtz Zentrum München
In May 2019, Caribou granted Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) a non-exclusive, worldwide license to use Caribou’s CRISPR-Cas9 genome editing technology to create genetically engineered mouse models for research purposes, including activities of the European Mouse Mutant Archive and the INFRAFRONTIER Research Infrastructure. The license enables Helmholtz Zentrum München and certain designated partners to deliver custom-generated mouse models for cutting-edge research under a limited use label license and will enable Helmholtz Zentrum München to pursue its goals of developing personalized medical approaches for the prevention and therapy of major common diseases such as diabetes mellitus, allergies, and lung diseases. Caribou receives royalties on sales of licensed products and is eligible for sales milestones.
Integrated DNA Technologies, Inc.
Caribou and Integrated DNA Technologies, Inc. (IDT), a producer of custom synthetic oligonucleotide-based technologies for genomics applications, entered into a non-exclusive license agreement in 2016 under which Caribou has granted IDT worldwide rights under Caribou’s intellectual property to commercialize CRISPR-Cas9 reagents. The reagents are sold by IDT subject to a research use limited label license, and Caribou receives royalties on reagents sold by IDT. IDT’s CRISPR-Cas9 reagents are used by customers conducting biological research across a broad range of scientific areas such as drug discovery, plant biology, and genomics and provide researchers with the ability to edit genomic DNA precisely and efficiently. View Press Release.
Intellia Therapeutics, Inc.
In 2014, Caribou co-founded Intellia Therapeutics to develop curative medicines utilizing Caribou’s CRISPR-Cas9 technology. Intellia has exclusive access to Caribou’s CRISPR-Cas9 technology for the development of new human gene and cell therapies as well as anti-viral therapies. Caribou has access to intellectual property developed by Intellia for areas outside of Intellia’s field. Intellia is developing both ex vivo and in vivo applications of Caribou’s CRISPR-Cas9 gene editing technology. Near-term ex vivo applications include the treatment of blood disorders and cancer. Caribou retains full rights to pursue opportunities for its technology platform in other valuable therapeutic markets, including antimicrobials and animal health. Intellia Therapeutics, Inc. is a publicly traded company, trading on NASDAQ under the symbol “NTLA.” View Press Release.
The Jackson Laboratory
Caribou granted The Jackson Laboratory (JAX) non-exclusive, worldwide rights to use Caribou’s CRISPR-Cas9 intellectual property to create genetically engineered mice for research purposes in 2016. Caribou’s market-leading CRISPR-Cas9 gene editing technology can accurately target and cut DNA to produce precise and controllable changes to the genome, which can be applied by JAX to create mouse models that better recapitulate human diseases enabling researchers to find better treatments faster. The license allows JAX to deliver custom-built mouse models sold under a research use limited label license, creating the next generation of predictive models for the new era of personalized medicine. In 2019, Caribou granted JAX a non-exclusive license to use Caribou’s CRISPR-Cas9 intellectual property to generate modified human and mouse cell lines and cell lines (e.g., induced pluripotent stem cells, embryonic stem cells, cancer cell lines, primary cells, etc.) for research services for end-user purchasers under a research use limited label license. Under both license agreements, Caribou receives royalties on sales of licensed products and services and is eligible for certain sales milestones. View Press Release.
Medical Research Council
In March 2019, Caribou granted the Medical Research Council (MRC), as part of UK Research and Innovation, a non-exclusive, worldwide license to use Caribou’s CRISPR-Cas9 intellectual property to create genetically engineered mice for research purposes. The license allows the MRC to deliver custom-designed mouse models sold under a limited use label license for research purposes. Caribou receives royalties on sales of licensed products and is eligible for a sales milestone.
Caribou granted Novartis an option for a non-exclusive, worldwide license for internal research under Caribou’s CRISPR-Cas9 technology in 2014 as part of a one-year research program to develop the Caribou CRISPR-Cas9 platform for drug target screening and validation technologies, and Novartis exercised its option for an internal research license in 2016. Caribou receives maintenance payments for the license to Novartis. The advancement of the Cas9-based platform for screening and validation will help further the development of new therapeutic products, and Caribou’s CRISPR-Cas9 technology can utilize guide RNAs specific for unique sequences and target a gene at numerous sites and therefore provide enhanced specificity. Novartis is an investor in Caribou’s Series A and Series B financing rounds. View Press Release.
Oxford Nanopore Technologies Ltd
Caribou and Oxford Nanopore Technologies Ltd (ONT), a UK-based company, entered into a non-exclusive license agreement in August 2019, under which Caribou has granted ONT worldwide rights to use CRISPR-Cas9 for nanopore sequencing and nanopore detection for research and diagnostics applications. ONT aims to disrupt the paradigm of biological analysis by making high performance, DNA/RNA sequencing technology that is accessible and easy to use. The license also includes the right for ONT to commercialize CRISPR-Cas9 nanopore sequencing and detection products and services. These products and services are sold by ONT subject to a research use limited label license, and Caribou receives royalties on sales and is eligible for certain sales milestones.
Caribou and RenOVAte Biosciences, Inc., a Maryland-based animal biotechnology company, entered into a non-exclusive license agreement in January 2019, under which Caribou has granted RenOVAte worldwide rights under certain intellectual property to use CRISPR-Cas9 to genome edit cattle, sheep, and pigs for research purposes and services. RenOVAte is in the business of performing sophisticated precision genome editing and genetic engineering in livestock species to address critical priorities of human and animal health. The license also includes the right for RenOVAte to conduct internal genome editing research. The products and services will be provided by RenOVAte subject to a limited use label license for research use only, and Caribou will receive royalties on such products and services.
Caribou and Takara Bio USA, Inc., a manufacturer and distributer of kits, reagents, and instruments for the life sciences, entered into a non-exclusive license agreement in 2020 wherein Caribou granted Takara worldwide rights under certain CRISPR-Cas9 intellectual property controlled by Caribou for Takara to sell research reagents and cell lines and, in Japan, genetically modified rats and mice subject to a limited use label license for research purposes only. Caribou received an upfront payment and royalties on such products sold by Takara.